Coverage of the top Medical companies.
Plans to File PMA Application and Bring Product to the US DURHAM, NC – December 14, 2016 – Bioventus, a global leader in orthobiologic solutions, today announced it has a new agreement with Galderma for DUROLANE, a single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis. […]
November 17, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the […]
GSK announces new data from phase III studies of sirukumab in adult patients with moderately to severely active rheumatoid arthritis
London – 16 November 2016 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced results from two pivotal phase III studies evaluating subcutaneous sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). The first study (SIRROUND-T), in patients who were refractory to or intolerant to […]
Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations
FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 16, 2016– Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations, with responsibility for commercial operations in North America, Europe and Japan. Mr. Meyers will become an officer of the company and member of Gilead’s senior leadership team. Mr. Meyers […]
Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers
Cooperative Research and Development Agreement (CRADA) assesses OX40 agonist, utomilumab and avelumab immuno-oncology assets alone and in various combinations November 14, 2016 – Pfizer Inc. (NYSE:PFE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). As part […]
Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed November 13, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three […]
Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib) Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen
Patients Taking Pfizer’s Celebrex (celecoxib) Experienced Fewer Gastrointestinal Events As Compared to Prescription Doses of Ibuprofen and Naproxen Study Findings Dispel Long Standing Perceptions of Excess Cardiovascular Risk Associated With Long Term Use Of Celebrex Results of PRECISION Study Presented at the Annual Meeting of the American Heart Association in New Orleans Provide Important Information […]
Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities
Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting® November 12, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting® 2016, which provide additional evidence supporting the […]
Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity
First seven participants, through a combined 103 weeks of observation as of Aug. 4, 2016, did not need infusions of factor IX concentrates to prevent bleeding Updated SPK-9001 data in hemophilia B to be presented at the Plenary Scientific Session at 58th American Society of Hematology Annual Meeting November 3, 2016 – PHILADELPHIA and NEW […]
Exclusive Platform Provides a Single Source to Analyze Online Patient Feedback and Comments BOSTON — OCT 27, 2016 –(BUSINESS WIRE)– Press Ganey today announced the introduction of the Press Ganey ® Consumer Analytics Solution , designed to help health care organizations monitor and analyze patient feedback across a variety of consumer-facing sources. Powerful analytics across […]
January 19, 2017 @ 9:00 am – January 21, 2017 @ 5:00 pm
The Gastrointestinal (GI) Cancers Symposium is a specialized oncology event designed to provide scientific and educational content for members of the GI cancer care and research community.
February 17, 2017 @ 9:00 am – February 19, 2017 @ 5:00 pm
The AAAS Annual Meeting is interdisciplinary and inclusive. Each year, our community gathers together to discuss recent developments in science and technology. Below you’ll find stories from many of our attendees.
February 19, 2017 @ 9:00 am – February 24, 2017 @ 5:00 pm
Attracting over 3,500 drug discovery and development professionals from over 40 countries in 2016, the Tri-Conference has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology.
February 19, 2017 @ 9:00 am – February 23, 2017 @ 5:00 pm
The 2017 HIMSS Annual Conference & Exhibition, February 19–23, 2017 in Orlando, brings together 40,000+ health IT professionals, clinicians, executives and vendors from around the world. Exceptional education, world-class speakers, cutting-edge health IT products and powerful networking are hallmarks of this industry-leading conference.